These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8558198)

  • 1. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
    Majlis A; Smith TL; Talpaz M; O'Brien S; Rios MB; Kantarjian HM
    J Clin Oncol; 1996 Jan; 14(1):196-203. PubMed ID: 8558198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Rios MB; Majlis A; Keating M; Freireich EJ; Kantarjian H
    J Clin Oncol; 1998 Oct; 16(10):3279-85. PubMed ID: 9779702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
    Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia.
    Przepiorka D; Thomas ED
    Bone Marrow Transplant; 1988 Mar; 3(2):113-9. PubMed ID: 3048475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
    O'Dwyer ME; Gatter KM; Loriaux M; Druker BJ; Olson SB; Magenis RE; Lawce H; Mauro MJ; Maziarz RT; Braziel RM
    Leukemia; 2003 Mar; 17(3):481-7. PubMed ID: 12646934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial cytogenetic studies in allografted patients with chronic myeloid leukemia.
    Bilhou-Nabera C; Bernard P; Marit G; Viard F; Gharbi MJ; Wen Z; Lacombe F; Broustet A; Reiffers J
    Bone Marrow Transplant; 1992 Apr; 9(4):263-8. PubMed ID: 1600414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
    Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD;
    Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
    Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
    Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Karyotype at relapse following allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Shah NK; Wagner J; Santos G; Griffin CA
    Cancer Genet Cytogenet; 1992 Jul; 61(2):183-92. PubMed ID: 1638501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.
    Fayad L; Kantarjian H; O'Brien S; Seong D; Albitar M; Keating M; Talpaz M
    Leukemia; 1997 May; 11(5):767-71. PubMed ID: 9180306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic myeloid leukemia. Karyotype changes].
    Rojas-Atencio A; Pineda-Del Villar L; Avila-León E; González-Ferrer S; Prieto-Carrasquero M; Soto M; González R
    Invest Clin; 1996 Sep; 37(3):167-75. PubMed ID: 8983354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia.
    Chase A; Pickard J; Szydlo R; Coulthard S; Goldman JM; Cross NC
    Genes Chromosomes Cancer; 2000 Mar; 27(3):278-84. PubMed ID: 10679917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isodicentric Philadelphia chromosome in accelerated phase of chronic myeloid leukemia.
    Pernice F; Squadrito G; Saitta A; Mazza G; Musolino C
    Cancer Genet Cytogenet; 1993 Apr; 66(2):113-6. PubMed ID: 8500097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia.
    Kloke O; Niederle N; Qiu JY; Wandl U; Moritz T; Nagel-Hiemke M; Hawig I; Opalka B; Seeber S; Becher R
    Br J Haematol; 1993 Mar; 83(3):399-403. PubMed ID: 8485045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
    Kantarjian HM; Smith TL; O'Brien S; Beran M; Pierce S; Talpaz M
    Ann Intern Med; 1995 Feb; 122(4):254-61. PubMed ID: 7825760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.